drugset / Trial / NCT06441994
Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer
Phase 1
Recruiting
15 enrolled
Osaka University
Japan Agency for Medical Research and Development · collab
NaSingle-groupOpen-labelTreatment
Summary
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Timeline
- Start
- 2024-05-24
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PSW-1025 | Other / unclassified | — | Intravenous |